EUVIMEDEUVIMED entdecken
Crossref

EE60 COST-EFFECTIVENESS OF TRIFLURIDINE/TIPIRACIL PLUS BEVACIZUMAB VERSUS REGORAFENIB IN REFRACTORY METASTATIC COLORECTAL CANCER IN KAZAKHSTAN

Talgat S. Nurgozhin, Shynggys Sergazy, Alima Almadiyeva, Alexander Kostyuk, Abrakhmanov Ramil

Value in Health · 2026-06 · 29 (6) · S74

DOI: 10.1016/j.jval.2026.03.355 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Talgat S. Nurgozhin und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Nurgozhin, T. S., Sergazy, S., Almadiyeva, A., Kostyuk, A., & Ramil, A. (2026). EE60 COST-EFFECTIVENESS OF TRIFLURIDINE/TIPIRACIL PLUS BEVACIZUMAB VERSUS REGORAFENIB IN REFRACTORY METASTATIC COLORECTAL CANCER IN KAZAKHSTAN. Value in Health, 29(6), S74. https://doi.org/10.1016/j.jval.2026.03.355

Vancouver

Nurgozhin TS, Sergazy S, Almadiyeva A, Kostyuk A, Ramil A. EE60 COST-EFFECTIVENESS OF TRIFLURIDINE/TIPIRACIL PLUS BEVACIZUMAB VERSUS REGORAFENIB IN REFRACTORY METASTATIC COLORECTAL CANCER IN KAZAKHSTAN. Value in Health. 2026;29(6):S74. doi:10.1016/j.jval.2026.03.355

BibTeX
@article{Nurgozhin2026,
  author = {Nurgozhin, Talgat S. and Sergazy, Shynggys and Almadiyeva, Alima and Kostyuk, Alexander and Ramil, Abrakhmanov},
  title = {EE60 COST-EFFECTIVENESS OF TRIFLURIDINE/TIPIRACIL PLUS BEVACIZUMAB VERSUS REGORAFENIB IN REFRACTORY METASTATIC COLORECTAL CANCER IN KAZAKHSTAN},
  journal = {Value in Health},
  year = {2026},
  volume = {29},
  number = {6},
  pages = {S74},
  doi = {10.1016/j.jval.2026.03.355}
}
Kostenlos starten →